pectolinarin has been researched along with hirsutanone in 2 studies
| Studies (pectolinarin) | Trials (pectolinarin) | Recent Studies (post-2010) (pectolinarin) | Studies (hirsutanone) | Trials (hirsutanone) | Recent Studies (post-2010) (hirsutanone) |
|---|---|---|---|---|---|
| 26 | 0 | 15 | 30 | 0 | 21 |
| Protein | Taxonomy | pectolinarin (IC50) | hirsutanone (IC50) |
|---|---|---|---|
| Spike glycoprotein | Betacoronavirus England 1 | 4.1 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 4.1 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 4.1 | |
| Procathepsin L | Homo sapiens (human) | 4.1 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 4.1 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 4.1 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 4.1 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 4.1 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 4.1 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 4.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, W; Choudhry, N; Xu, D; Yang, Z; Zanin, M; Zhao, X | 1 |
| Christy, MP; Gerwick, L; Gerwick, WH; Uekusa, Y | 1 |
2 review(s) available for pectolinarin and hirsutanone
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; SARS-CoV-2; Small Molecule Libraries | 2020 |
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
Topics: Animals; Antiviral Agents; Biological Products; COVID-19 Drug Treatment; Drug Development; Genome, Viral; Humans; RNA Virus Infections; RNA Viruses; Virus Replication | 2021 |